SARMs: What Clinicians Need to Know About the Class

Selective androgen receptor modulators — SARMs — include compounds sold as ostarine or MK-2866, ligandrol or LGD-4033, RAD-140, andarine and others. They appear in this formulary for one reason: they are bundled with peptide protocols by online vendors, so clinicians encounter them in the same conversations. They are not peptides. They are small molecules acting on a completely different receptor system.

This guide situates SARMs within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.

What SARMs actually are

SARMs are non-steroidal small molecules that bind the androgen receptor. The design goal was tissue selectivity: activate the receptor in muscle and bone, where the anabolic effect is wanted, while producing less activity in prostate, skin and hair follicles, where androgen effects are unwanted.

That is a legitimate pharmacologic objective, and several SARMs were investigated by pharmaceutical companies for cachexia, osteoporosis and muscle wasting. None completed development to approval. The compounds circulating today are largely abandoned or never-completed development candidates that migrated into the consumer market.

The distinction from peptides matters and is not pedantic. Peptides are chains of amino acids acting at peptide hormone receptors. SARMs are small molecules acting at a nuclear hormone receptor that directly regulates gene transcription. Different chemistry, different pharmacology, different risks — and different regulatory frameworks.

The documented risks

Hepatotoxicity is the most serious signal. Case reports of drug-induced liver injury associated with SARM use appear in the medical literature, including cholestatic injury with significant jaundice. These are published clinical cases, not theoretical concerns.

Suppression of the hypothalamic-pituitary-gonadal axis is expected and common. Because SARMs activate the androgen receptor, they trigger the same negative feedback that exogenous testosterone does, lowering endogenous testosterone, LH and FSH. Suppression of spermatogenesis follows, and recovery timelines are unpredictable. Patients frequently do not anticipate this.

Adverse lipid changes, particularly reductions in HDL cholesterol, are consistently reported. Longer-term cardiovascular effects are uncharacterized because no long-term controlled human trials exist.

The FDA has issued a public safety notification warning against use of body-building products containing SARMs, citing risks including liver injury and increased cardiovascular risk, and has sent warning letters to distributors.

What is actually in the bottle

There is a further problem that patients almost never consider. Independent analytical testing of products sold as SARMs has repeatedly found that a large proportion do not contain what the label states — a published analysis of products purchased online found only about half contained the SARM advertised, with substantial discrepancies in stated versus actual content, unlisted substances present, and some products containing no active compound at all.

This means a patient using these products often cannot say what they have taken. It also means that a clinical picture — abnormal liver enzymes, suppressed testosterone — cannot be attributed confidently to the named compound, because the named compound may not be the one involved.

For a clinician, the practical implication is to treat the exposure as unknown rather than assuming the label.

How this comes up in practice

Patients using SARMs are typically young, generally healthy, and often not disclosing use unless asked directly. They should be asked directly, without judgment, because the relevant workup is specific: liver function testing, a lipid panel, and a full hypogonadism evaluation including LH, FSH and total testosterone.

The framing that lands is honest rather than dismissive: these were real drug candidates, they were not abandoned for lack of effect but were never shown safe enough to approve, the products sold are frequently not what they claim, and the axis suppression is real and may take time to recover. Patients seeking anabolic effects deserve a genuine conversation about what training, nutrition, and where appropriate legitimate medical therapy can accomplish.

SARMs are also prohibited in sport at all times under the World Anti-Doping Agency Prohibited List, which is relevant to any competitive athlete.